BioWorld Asia

Nov. 10, 2010

Celtic Fund May not Reach $700M as Final Closing Nears

LONDON – After stalling during the financial crisis, Celtic Therapeutic Holdings LP is coming to the end of marketing its first fund and expects to have the final closing by the end of the year. (BioWorld International) Read More

Wilex Acquiring Heidelberg Pharma for $27M in Stock

Immune Mechanism Promises New Approach to Antivirals

Cosmo Poised for Filings for Ulcerative Colitis Drug

Zealand Pharma Seeking $126M in Danish IPO

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 24, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Illustration of tau accumulating in a neuron cell.

ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

BioWorld

ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...